Why the study?
Does Interleukin-1 blockade improve clinical outcomes in patients with cardiovascular diseases?
Does Interleukin-1 blockade improve clinical outcomes in patients with cardiovascular diseases?
This review highlights the emerging role of IL-1 blockade as a targeted anti-inflammatory therapy across a spectrum of cardiovascular diseases.
IL-1 blockade should not yet change practice in HF, pericarditis, or post-MI; leaves open need for confirmatory RCTs.
Cardiovascular diseases are the leading cause of death worldwide. Research in the last two decades has emphasized the inflammatory process as a key component in the pathogenesis of many of them. The Interleukin-1 family is a pivotal element of inflammation and has been well studied as a therapeutic target in various inflammatory states. Recent trials have explored the effect of Interleukin-1 blockade in cardiovascular diseases and initial evidence of the relevance of such treatment in this field of medicine accumulate. This review will describe the role of Interleukin-1 in heart diseases and the potential therapeutic effect of its blockade in such diseases.
No takes yet. Share an insight, caveat, or question.
Szekely et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: